Published in Cancer Weekly, August 5th, 2003
Study findings demonstrate that 17-AAG and 5-fluorouracil (5-FU) administered in combination against human colon cancer cell lines results in a synergistic growth inhibiting effect.
According to study investigators, the combination of 17-AAG and 5-FU warrants further investigation as an anticancer therapy. Kosan and the National Cancer Institute (NCI) are collaborating to codevelop 17-AAG and other geldanamycin derivatives, and are planning to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.